Similar articles

• Transient factor VIII inhibitor and treatment with monoclonal-antibody-purified factor VIII.

  Montoro JB, Rodríguez S, Altisent C, Tusell JM. Montoro JB, et al. Lancet. 1991 May 18;337(8751):1222. doi: 10.1016/0140-6736(91)92891-5. Lancet. 1991. PMID: 1673757 No abstract available.
• Factor VIII:C inhibitor associated with monoclonal-antibody-purified FVIII concentrate.

  Rodell MB, Bergman GE. Rodell MB, et al. Lancet. 1990 Aug 11;336(8711):373. doi: 10.1016/0140-6736(90)91912-t. Lancet. 1990. PMID: 1975350 No abstract available.
• The development of the technology and capacity for the production of factor VIII for the treatment of hemophilia A.

  Aronson DL. Aronson DL. Transfusion. 1990 Oct;30(8):748-58. doi: 10.1046/j.1537-2995.1990.30891020338.x. Transfusion. 1990. PMID: 2120808 Review. No abstract available.
• Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C.

  Lusher JM. Lusher JM. Ann Hematol. 1991 Sep;63(3):138-41. doi: 10.1007/BF01703244. Ann Hematol. 1991. PMID: 1932288 No abstract available.
• Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor.

  Chavin SI, Siegel DM, Rocco TA Jr, Olson JP. Chavin SI, et al. Am J Med. 1988 Aug;85(2):245-9. doi: 10.1016/s0002-9343(88)80353-x. Am J Med. 1988. PMID: 3135752 Review. No abstract available.